Schrodinger Grants Stock Options and RSUs to New Employees
Schrodinger granted a non-statutory stock option to purchase 1,875 shares of the company's common stock to one newly hired employee and restricted stock units with respect to 18,766 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The stock option has an exercise price of $12.05 per share, equal to the closing price of the company's common stock on May 18, 2026. The stock option has a ten-year term and vests over four years, with 25 percent of the shares underlying the option vesting when such employee completes 12 months of continuous service measured from the employment start date and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon the employee's completion of each additional month of service over the 36-month period following the first anniversary of the employment start date. The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee's completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date.
Trade with 70% Backtested Accuracy
Analyst Views on SDGR
About SDGR
About the author

- Importance of Biological Knowledge: MindWalk Holdings Corp. emphasizes that the true value in drug discovery lies in the connectivity of biological knowledge rather than just AI models, a perspective highlighted during the investor panel on June 15, which could influence industry investment directions.
- Technological Innovation: The launch of MindWalk's ReefIQ™ biological context layer technology connects 660 million biological patterns and 25 billion relationships, aiming to enhance AI model accuracy and reduce errors caused by fragmented data, thereby increasing the likelihood of successful drug discovery.
- Financial Performance: In its Q3 fiscal 2026 report, MindWalk reported revenue of CAD 4.2 million, a 52% year-over-year increase, and signed its first annual contract for the LensAI platform, marking a successful transition towards a sustainable revenue model.
- Market Competition: MindWalk faces intense competition in the AI drug discovery space from companies like Absci and Recursion, which tackle similar issues at different layers, and its biological context layer strategy may provide a unique market positioning.
- Recursion's Growth Potential: Recursion Pharmaceuticals reported nearly $74.7 million in revenue for FY 2025, reflecting a 26.9% year-over-year increase, despite a substantial net loss of approximately $644.8 million, highlighting the high costs and risks associated with drug discovery.
- Schrödinger's Steady Performance: Schrödinger generated about $255.9 million in revenue for FY 2025, marking a 23.3% increase, with a net loss of roughly $103.3 million, indicating stable growth in its software business and improved financial health.
- Risks and Challenges: Recursion faces significant regulatory hurdles and relies heavily on a small number of partners, meaning that the termination of agreements with companies like Roche could severely impact its revenue, while Schrödinger's dependence on unpredictable software sales cycles may affect revenue stability.
- Valuation Comparison: Recursion trades at a price-to-sales ratio of 26.1x, significantly higher than Schrödinger's 4.3x, reflecting a market premium on its future potential, but also indicating a higher investment risk.
- Revenue Growth Comparison: Recursion Pharmaceuticals reported nearly $74.7 million in revenue for FY 2025, reflecting a 26.9% increase, yet it faced a staggering net loss of approximately $644.8 million, highlighting the high costs associated with clinical trials and digital infrastructure, leaving its future profitability uncertain.
- Software Revenue Stability: Schrödinger generated around $255.9 million in revenue for FY 2025, marking a 23.3% increase, and while it reported a net loss of roughly $103.3 million, this represents an improvement from the previous year, indicating a gradual stabilization and expansion of its software business.
- Market Risk Analysis: Recursion's reliance on a small number of large partners like Roche and Bayer poses significant revenue risks, as the termination of any agreement could severely impact its income, compounded by competitive pressures from larger firms.
- Divergent Future Outlooks: Although Schrödinger is also currently operating at a loss, management anticipates a significant reduction in operating expenses in 2026, with annual contract value expected to grow by 10% to 15%, suggesting potential growth momentum for its business.
- Stock Option Grant: On May 18, 2026, Schrödinger granted a non-statutory stock option to purchase 1,875 shares at an exercise price of $12.05 per share to a newly hired employee, aligning with the company's strategic goal of attracting talent.
- Restricted Stock Units: The company also awarded 18,766 restricted stock units (RSUs) to seven new employees, which were granted under the 2021 Inducement Equity Incentive Plan, aimed at enhancing long-term employee retention.
- Grant Conditions: The stock options vest over four years, with 25% vesting after 12 months of service and the remainder vesting monthly, ensuring employees remain with the company to fully realize their benefits, thereby increasing loyalty.
- Company Background: Founded in 1990, Schrödinger employs approximately 800 people and is focused on transforming molecular discovery through its computational platform, serving the global biotechnology and pharmaceutical sectors, showcasing strong market competitiveness.
- Improved Market Conditions: Biotech investors are experiencing a friendlier macro environment not seen in years, with stabilizing interest rates, increased FDA activity, and pharmaceutical companies holding billions in cash while facing patent cliffs, creating a favorable backdrop for smaller biotech firms.
- Schrödinger's Growth Potential: Schrödinger (SDGR) is guiding for a 10% to 15% growth in annual contract value (ACV) for 2026, reaching between $218 million and $228 million, showcasing strong growth potential in drug discovery, while reporting total revenue of $256 million for 2025, making it one of the few profitable AI-driven biotech companies.
- Sarepta's Commercial Challenges: Sarepta (SRPT) reported net product revenue of $1.86 billion for 2025, and despite ongoing safety controversies surrounding its Elevidys gene therapy, it maintains a 2026 revenue guidance of $1.2 billion to $1.4 billion, demonstrating a robust commercial foundation in the Duchenne muscular dystrophy market.
- NRX's Regulatory Progress: NRX Pharmaceuticals (NRXP) has received positive feedback from the FDA regarding its lead drug candidate, with a potential decision expected this summer, and while it faces financing and execution risks, its focus on severe depression treatments is attracting increasing investor interest.
- AI-Driven Drug Discovery: Schrödinger reported total revenue of $256 million in 2025, with $200 million from software, and management anticipates a 10% to 15% growth in annual contract value for 2026, highlighting its strong potential in drug development and market demand.
- Sarepta's Gene Therapy Challenges: Sarepta achieved net product revenue of $1.86 billion in 2025, and despite safety concerns surrounding Elevidys, the company maintains its revenue guidance of $1.2 billion to $1.4 billion for 2026, indicating its ongoing competitiveness in the gene therapy market.
- NRX's Regulatory Progress: NRX Pharmaceuticals is developing treatments for severe depression, and recent FDA feedback indicated no major issues with its preservative-free ketamine, with a potential decision expected this summer, which could significantly increase market attention if approved.
- Improving Macro Environment: Biotech investors are experiencing a more favorable macro environment with stabilizing interest rates and increased FDA activity, providing a fertile backdrop for smaller biotech companies with strong pipelines and differentiated technologies to thrive.











